Literature DB >> 27054931

Ondansetron Use in Pregnancy.

Lara L Siminerio1, Lisa M Bodnar, Raman Venkataramanan, Steve N Caritis.   

Abstract

The American College of Obstetricians and Gynecologists recommends early treatment of nausea and vomiting of pregnancy to stop progression to hyperemesis gravidarum. Nausea and vomiting and hyperemesis gravidarum typically occur during the first trimester, the sensitive time for exposure to teratogens because organogenesis is occurring in the embryo. An efficacious treatment used widely across the United States for both nausea and vomiting of pregnancy and hyperemesis gravidarum is ondansetron. Recent studies have provided conflicting findings on the safety of ondansetron during pregnancy. There are numerous limitations in the current literature on ondansetron safety including exposure to the medication is not limited to sensitive windows of organogenesis, there is a lack of information on dosing and compliance, self-reports of exposure are commonly used, an inadequate accounting exists for other factors that may explain the relationship between ondansetron exposure and the adverse outcome, and there exists a lack of biologic plausibility by which ondansetron might cause harm. It is the authors' opinion that current data do not support a reluctance to treat women with ondansetron in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27054931     DOI: 10.1097/AOG.0000000000001375

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  1 in total

1.  Getting through the day: a pilot qualitative study of U.S. women's experiences making decisions about anti-nausea medication during pregnancy.

Authors:  Marlaine Figueroa Gray; Clarissa Hsu; Linda Kiel; Sascha Dublin
Journal:  BMC Pregnancy Childbirth       Date:  2018-12-04       Impact factor: 3.007

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.